R&D

  • overview
  • Technologies
  • R&D Pipeline
  • Open Innovation
  • Achivement

OverviewOverview

Samyang Biopharm aims to become a globally recognized research center specialized in DDS (Drug Delivery System) Technology and biodegradable Medical Devices Samyang Biopharm aims to become a globally recognized research center specialized in DDS (Drug Delivery System) Technology and biodegradable Medical Devices

Medicine Medicine

Samyang Biopharmaceuticals Corp., which focuses all its efforts upon research on a fresh concept of the drug delivery system (DDS) has continually succeeded in developing innovative products one after another. Genexol® PM and Nanoxel® M, which are anticancer drugs that applied the chemically synthesized nano-polymer DDS, have been commercialized as a rare case.

We have developed safe and efficacious medical patches, such as a patch for cancer patients with severe-to-moderate pain, a smoking cessation patch, an anti-inflammatory analgesic patch, via the application of TDS (Transdermal Delivery System) technology that delivers drugs through the skin.

In the field of API (Active Pharmaceutical Ingredients), we have developed the plant cell culture method and succeeded in the world’s first mass production of paclitaxel as raw materials that are used in the anticancer drug.

Recently, we have been focusing on developing treatment to maximize the effect of chemotherapy in combination with the anticancer drug in nano form and innovative technology that will deliver a nucleic acid-based agent such as siRNA, mRNA, and pDNA. Such an innovative drug delivery system will open up new opportunities in the field of the monoclonal antibody, antibody-drug conjugate (ADC), and recombinant protein.

Medical Devices Medical Devices

Samyang Biopharmaceuticals Corp., released Trisorb®, which is absorbable surgical suture that is absorbed into the body after a certain amount of time, for the first time domestically and only the third time worldwide in 1996. Currently, we are exporting this product to about 45 countries. Also, through the gradual success in commercializing Surgisorb®, Monosorb®, Neosorb®, and an antimicrobial suture, Neosorb® Plus, we have completed all of the suture portfolio. In addition to these, Biomesh®, which is a periodontal tissue regenerator, and SurgiGuard®, which is a hemostatic agent, are the key products that represent the medical devices of Samyang Biopharmaceuticals Corp.,

Samyang Biopharmaceuticals Corp., has been developing wound managing and sealing products that use biodegradable materials based on accumulated technology in biodegradable material and product manufacturing. We continuously strive to develop high functional and high value added medical devices, so much so that we are expanding to additional fields such as 3D materials and plastic surgery. Also, to secure world leading technology, we have established a long-term plan and are actively promoting R&D in the field of tissue regeneration and angiology such as the biodegradable stent.